Jefferies Upgrades BeOne Medicines to Buy, Raises Price Target to $380

Benzinga Newsdesk www.benzinga.com Positive 81.8%

Neg 0% Neu 0% Pos 81.8%

Jefferies analyst Faisal Khurshid upgrades BeOne Medicines (NASDAQ:ONC) from Hold to Buy and raises the price target from $333 to $380.